BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

11:47 AM
 | 
Jul 21, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Phase III CAMELLIA-TIMI CVOT for Belviq ongoing

Eisai Co. Ltd. (Tokyo:4523, Tokyo, Japan) said an independent DMC recommended continuation of the Phase IIIb/IV CAMELLIA-TIMI 61 cardiovascular outcomes trial of Belviq lorcaserin (APD356) for chronic weight management. The DMC based its recommendation on a pre-specified interim safety analysis evaluating the incidence of major adverse cardiovascular events (MACE), comprising myocardial infarction (MI), stroke and cardiovascular (CV) death.

Read the full 269 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >